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if the trend continues. It is not clear that such
findings would necessarily drive a return of the
Uphold LITE or a similar device for use. In the
meantime, surgeons will best serve their pa-
tients by continuing to open wide-ranging and
comprehensive discussions about goals and
preferences with their patients wishing to con-
sider surgery. No single option is ideal for ev-
ery woman or without risk of recurrence or
complications.—ACW)
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ABSTRACT
It is estimated that urinary incontinence (UI) affects up to 58% of women and has a significant negative impact on their
quality of life. Mixed UI includes both stress and urgency incontinence and is present in up to half of women with UI. Mixed
incontinence is often consideredmore severe thanUI, responds poorly to treatment, and is more difficult tomanage than either
urinary condition alone. Studies evaluating treatments that simultaneously improve both components of mixed UI are lacking.
First-line treatment includes conservative therapy, behavioral and pelvic floor muscle training, followed by overactive bladder
medication. Surgerywith sling procedures can worsen urgency, and for this reason, clinical guidelines recommend treating the
urgency component prior to consideration of surgery. Observational data support the effectiveness of midurethral sling surgery
for treating the stress component. However, there are only limited data among womenwith mixed incontinence or approaches to
improve urgency incontinence outcomes after midurethral sling. One strategy that has the potential to treat stress and urgency
incontinence concurrently in women with mixed UI is combining conservative therapy with surgery, but the efficacy among
women with mixed incontinence is unclear.
The aim of this multicenter, randomized, superiority trial was to determine whether combining behavioral and pelvic floor
muscle therapy with midurethral sling is more effective than sling alone for improving UI symptoms in women with mixed
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UI. Subjects were women 21 years or older, who reported moderately to severely bothersome symptoms of stress and urgency
incontinence for at least 3 months and documented at least 1 stress and 1 urgency incontinence episode on a 3-day bladder
diary. The study was conducted in the United States across 9 sites in the Pelvic Floor Disorders Network. Patients were en-
rolled between October 2013 and April 2016, with final follow-up in October 2017. Conservative therapy, behavioral and pelvic
floor muscle therapy, included 1 preoperative and 5 postoperative sessions through 6months combinedwith midurethral sling
(n = 209) or sling alone (n = 207). Surgeons and outcome assessors were masked, but patients and interventionists were not.
Change in mixed UI symptoms at 12 months, the primary outcome, was measured using the Urogenital Distress Inventory
(UDI) long-form total score (range, 0–300 points; minimal clinically important difference, 35 points; higher scores indicate
greater symptom severity).
Mean age was 54.0 (SD, 10.7) years. Of the 480 women randomized, 416 were eligible (209 combined, 207 sling only), had
postbaseline outcome data, andwere included in primary analyses. In the combined group, the UDI score significantly decreased
(from 178.0 points at baseline to 30.7 points at 12months); the adjusted mean change was−128.1 points, with a 95% confidence
interval (CI) of −146.5 to −109.8.
In the sling-only group, the UDI score significantly decreased (from 176.8 to 34.5 points); the adjusted mean change was
−114.7 points, with a 95% CI of −133.3 to −96.2. The model-estimated between-group difference of −13.4 points (95% CI,
−25.9 to −1.0; P = 0.04) did not meet the minimal clinically important difference threshold for clinical importance. Serious
adverse events occurred in 10.2% of the participants (8.7% combined and 11.8% sling only). Only 2.3% of these were con-
sidered to be possibly, probably, or definitely related to the intervention.
These data show that among women with mixed UI, behavioral and pelvic floor muscle therapy combined with midurethral
sling surgery, when compared with surgery alone, resulted in a small statistically significant difference in UI symptoms at
12 months. The difference, however, did not meet the prespecified threshold for clinical importance.
EDITORIAL COMMENT
(Despite the significant prevalence and symptom
bother of mixed UI in the overall population of
women complaining of UI, consistent, evidence-
based recommendations for treatment have been
hard to establish. Traditional treatment algorithms
have focused on segregating the overall symp-
toms into 2 categories (stress and urge), often
with distinct plans for management. Often, pelvic
floor physical therapy as the most noninvasive
therapy is recommended first, to maximize treat-
ment safety, but while it can be effective for both
stress and urge UI (Cochrane Database Syst Rev
2010; CD005654), manywomenbecomedissatis-
fied with this initial form of treatment andmove on.
Regrettably, overactive bladder medications can
be similarly ineffective or poorly tolerated in the
long term (Int J Clin Pract 2011;65:567–585). Ulti-
mately, many womenwith mixed UI resort to surgi-
cal treatment despite traditional teaching that it
may worsen urge urinary incontinence (UUI) symp-
toms. Increasing evidence in the past 10 years has
indicated this is not likely the case (Int Urogynecol J
2011;22:923–932), prompting more comfort with
studying surgery as a treatment option formixedUI.
Clinical trials for mixed UI have been hampered
by hesitance to recruit women with significant se-
verity of UUI, challenges in setting appropriate
treatment outcomes, lack of power to detect both
SUI and UUI outcomes, and even lack of agree-
ment on a definition of mixed UI. As an example,
in 2009, theUrinary Incontinence TreatmentNetwork
published their experience with the MIMOSA trial
protocol, which observed 27 women enrolled into a
feasibility study over 4 to 5 months where the target
study population for the main protocol was to be
1190. Problems were attributed to strict inclusion
criteria, trial design, and divergent treatment ap-
proaches (Clin Trials 2009;6:355–364).
This study protocol was carefully designed and
informed by these past experiences. The primary
outcome at 1 year was chosen as the change from
baseline in the Urinary Distress Inventory total
score, because that scale is validated and patient
reported and has subscales that reflect stress, irri-
tative, and obstructive symptoms. The Urinary
Distress Inventory discriminates between UI clini-
cal groups and is responsive to clinical change. In-
clusion and exclusion criteria were chosen to
include women with significant severity of both
stress and urge UI who were good candidates
for surgical management of their SUI. Great care
was taken to design a comprehensive program
of combined behavioral and pelvic floor physical
therapy, which could be standardized via a cen-
tral training program but ultimately generalizable
among pelvic floor therapists.
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Ultimately, the ESTEEM study found that women
with mixed UI who had perioperative behavioral
and physical therapy around the time of their sling
surgery did marginally better in controlling their UI
symptoms than women who underwent sling
alone, but the differences did not reach the level
of clinical significance as defined by the study.
Women in the combined therapy group did have
slightly fewer UI episodes per day and were less
likely to receive additional treatment for UI symp-
toms 1 year after surgery. The ESTEEM study
did not show that urgency symptoms were wors-
ened by sling surgery; in fact, the opposite was
true. The improvement in mixed UI in women hav-
ing sling alone was really quite consistent and is a
striking finding. More than 80% of patients in both
groups reported being globally much better or
very much better. The bottom-line treatment im-
pact is that women with mixed UI should be eval-
uated to see if they are candidates for surgical
management of their UI and can reliably expect
improvement even when they have significant
preoperative UUI. Taking the traditional stepwise
approach by segregating the nature of UI symp-
toms can lead to unnecessary delay of surgery
and therefore delay of relief. Some women with
mixed UI will benefit from behavioral and pelvic
floor physical therapy, which certainly can be offered
as solo therapy in those who desire or used concur-
rently with surgery. This study did not evaluate
whether women with persistent or worsening UUI
symptoms post–sling surgery might benefit from
postoperative behavioral and physical therapy,
but clearly that option is safe to pursue.—ACW)
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ABSTRACT
Animal models suggest that increased uterine prolactin concentration is a risk factor for adenomyosis. Prolactin is produced
in the human endometrium, myometrium, and the pituitary gland and acts as a smooth muscle cell mitogen in vitro. Both mu-
rine and human studies suggest a link between the action of antidepressants and prolactin in the development of adenomyosis.
Bromocriptine, a dopamine agonist, inhibits pituitary secretion of prolactin and is the criterion standard of treatment for
hyperprolactinemia. This agent is inexpensive and safe and has no serious adverse effects.
The aim of this pilot study was to evaluate the effect of bromocriptine on menstrual bleeding and pain in women with
adenomyosis. Participants were 23 women aged 35 to 50 years with diffuse adenomyosis characterized by regular heavy men-
strual bleeding (HMB). Patients were enrolled from a university hospital in Sweden and a tertiary care hospital in the United
States. A total of 19 patients completed 6 months of treatment with vaginal bromocriptine 5 mg daily. Study staff and partic-
ipants were not blinded to treatment. Several self-administered validated questionnaires were utilized to assess changes in
symptoms from baseline to 3 and 6 months of treatment and at 9 months (3 months after cessation of bromocriptine). The
questionnaires included Pictorial Blood Loss Assessment Chart (PBLAC), Aberdeen Menorrhagia Clinical Outcomes Ques-
tionnaire, visual analog scale for pain, McGill Pain Questionnaire, Endometriosis Health Profile (EHP-30), Female Sexual
Function Index, and the Fibroid Symptom Quality of Life (UFS-QOL) symptom severity and health-related quality-of-life
subscores. The Wilcoxon signed rank test was used to compare scores between baseline and 9 months. All treatment scores
were compared with baseline.
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